How Your Practice Can Help the Prior Auth Crisis

You already know this story. A physician prescribes an MPK. You do the evaluation, confirm the medical necessity, create a plan and submit a prior authorization request. Then you wait. The insurer comes back with a denial — or worse, silence. Your patient, who was told they'd have a new prosthesis in a few weeks, is now calling your front desk every other day wondering what happened to their leg. 

This isn't an exception. According to a June 2026 report from the Commonwealth Fund, one in five working-age adults with private insurance had a coverage denial for doctor-recommended care in the past year. For O&P practices, that statistic lands differently than it might for other healthcare providers. We're often the ones absorbing the administrative burden of fighting denials on behalf of patients who don't fully understand the process, don't know they have rights, and may not have the energy or resources to fight on their own. 

The Commonwealth Fund data puts real consequences on what we already know from experience. Of the patients who received a denial, 41% said it led to delayed care, and 28% reported that their health got worse as a direct result. For an amputee waiting on a prosthesis, "delayed care" is not a statistic. It's additional time in a wheelchair, additional falls, additional deconditioning, and a longer road to functional independence. 

Clinical and economic research shows these delays have a real cost. A peer-reviewed study published in PM&R found that patients who received a lower-limb prosthesis within three months of amputation had total healthcare costs approximately 25% lower — roughly $25,000 less — over the first 12 months post-amputation compared to those who did not receive a prosthesis in that window. That's not a marginal difference. That's the cost of an insurance denial measured in real dollars, on top of the real suffering. 

The Dobson DaVanzo research commissioned by the Amputee Coalition and AOPA reinforces this from a different angle: patients who received timely prosthetic care had comparable or lower total Medicare payments than matched patients who did not — despite the relatively high cost of the prosthesis itself. The device pays for itself in downstream costs avoided. When a payer denies or delays a prosthesis authorization, they are not saving money. They are shifting costs — often back to themselves, and always onto the patient. 

Every week of delay in getting a new amputee ambulatory has consequences that compound. Deconditioning sets in quickly in post-amputation patients. Residual limb volume fluctuates. Psychological readiness for rehabilitation — already fragile in many new amputees — erodes with every unanswered phone call and every postponed appointment. Research consistently shows that early mobility and ambulation are associated with better long-term functional independence, while delay increases the risk of clinical complications. 

A separate Dobson DaVanzo study on rehabilitation setting found that limb-loss patients treated with timely, intensive inpatient rehabilitation returned home an average of 16 days earlier, remained home nearly three months longer, and had lower mortality and fewer readmissions compared to those who received less intensive care. The implication for prior auth delays is direct: every week a patient sits waiting for approval is a week of rehabilitation momentum lost — momentum that is genuinely difficult to recover. 

For working-age amputees, the stakes extend to their livelihood. Return-to-work outcomes after lower-limb amputation are strongly tied to the speed and quality of rehabilitation. Delayed prosthetic fitting means delayed return to work — lost wages for patients, extended disability claims for employers, and higher long-term costs for payers. The same payers whose denial triggered the delay. 

Where Your Practice Can Make a Real Difference

Your practice cannot fix a broken prior authorization system. But you can control several things that meaningfully change outcomes for your patients. These are not theoretical best practices — they are operational habits. 

• Write your clinical notes so that they speak the payer's language from day one. Most initial denials aren't about fraud or even clinical disagreement — they're about documentation that doesn't meet the specific language a payer's medical reviewer is looking for. Vague justifications rarely hold up. Functional outcome language tied to specific K-level goals, activity demands, vocational requirements, and the cost consequences of not providing the device gives reviewers far less room to deny. 

• Coach your patients on their right to appeal. The Commonwealth Fund found that only about half of denied patients even attempted an appeal, primarily because they didn't know they could, or didn't believe it would work. A simple one-page handout from your practice explaining the appeals process and the patient's rights can change that. Patients who feel informed are more likely to follow through. 

• Know when to request a peer-to-peer review. When a prior auth denial is clinically unjustifiable, a peer-to-peer review — where you and the prescribing physician speak directly with the payer's medical reviewer — is often the most effective next step. Coming in prepared with functional outcome data and the published evidence on cost-effectiveness, including the Dobson DaVanzo findings, gives that conversation a much better chance of ending in an approval. 

• Track your authorization approval rates by payer. Some commercial payers have voluntary 'gold carding' programs that may extend to certain O&P codes. It's worth asking your payer representative whether your practice's approval history qualifies — but don't count on it as a reliable path. You can only make that argument if you're tracking the data. (see your OPIE Business Intelligence Dashboard) 

What the Research Is Telling Payers (Even If They're Not Listening Yet)

The clinical and economic evidence against delaying prosthetic and orthotic care is substantial and growing. The Dobson DaVanzo studies, the PM&R cost research, and the Commonwealth Fund's coverage denial report are all pointing in the same direction: denying or delaying medically necessary O&P care costs more in the long run — for payers, for the healthcare system, and most of all for patients.